

FCR 6

Office of the President
February 21, 2025

Members, Board of Trustees:

ACCEPTANCE OF CHARITABLE GIFT COMMITMENT FROM NICHOLAS S. HELLMANN AND SUSAN DESMOND-HELLMANN TO BENEFIT THE COLLEGE OF MEDICINE

Recommendation: that the Board of Trustees accept a charitable gift commitment totaling \$2,100,000 from Nicholas S. Hellmann and Susan Desmond-Hellmann to establish and support an endowed chair fund named the “Dr. Nicholas Hellmann Endowed Chair in Infectious Diseases and Immunology Research” and a companion non-endowed chair fund named the “Dr. Nicholas Hellmann Chair in Infectious Diseases and Immunology Research” in the College of Medicine, Department of Microbiology, Immunology, Molecular Genetics.

Background: Nicholas S. Hellmann, MD, is a 1982 alumnus of the College of Medicine and is currently serving as the Strategy and Science Advisor at the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and a consultant to the Bill and Melinda Gates Foundation on HIV-related issues. He previously worked from June 2008 to April 2014 as the EGPAF Executive Vice President of Medical and Scientific Affairs, responsible for strategic oversight and direction of the Foundation’s research initiatives and medical programs focused on ending HIV/AIDS in children and providing HIV prevention, care, and treatment services to children, women, and families at over 7000 foundation-supported sites in 14 countries across the globe.

Susan Desmond-Hellmann, MD, MPH, former CEO of the Bill and Melinda Gates Foundation and a member of the President’s Council of Advisors on Science and Technology, is a physician-scientist who led the development of the first gene-targeted drug for treating breast cancer. Dr. Desmond-Hellman’s medical, scientific and philanthropic career spans 40 years, from academic medicine and clinical practice studying cancer and HIV/AIDS, to running research and product development at some of America’s top biotechnology companies, to leading higher education at one of California’s marquis graduate institutions, to running the world’s largest private foundation. She served as Chancellor of the University of California, San Francisco, from 2009 to 2014, the first woman to hold the position. In 1995, Dr. Desmond-Hellmann began working at Genentech, advancing to the role of President of Product Development from 2005 to 2009, overseeing pre-clinical and clinical development, business development and product portfolio management. Prior to joining Genentech, she was Associate Director,

Clinical Cancer Research at Bristol-Myers Squibb Pharmaceutical Research Institute. She has also served as a member of the Board of Directors for both Facebook Inc. and Procter & Gamble.

Action taken: Approved Disapproved Other _____